STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer

Xiaoman Li; Lufeng Zheng; Feng Zhang; Jinhang Hu; Jinjiang Chou; Yu Liu; Yingying Xing; Tao Xi

doi:10.18632/oncotarget.8099

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer

Xiaoman Li, Lufeng Zheng, Feng Zhang, Jinhang Hu, Jinjiang Chou, Yu Liu, Yingying Xing and Tao Xi _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:23197-23211. https://doi.org/10.18632/oncotarget.8099

Metrics: PDF 2558 views | HTML 4515 views | ?

Abstract

Xiaoman Li1,2,*, Lufeng Zheng1,2,*, Feng Zhang1,2, Jinhang Hu1,2, Jinjiang Chou1,2, Yu Liu3, Yingying Xing1,2 and Tao Xi1,2

1 School of Life Science and Technology, China Pharmaceutical University, Nanjing, People′s Republic of China

2 Jiangsu Key Laboratory of Carcinogenesis and Intervention, China Pharmaceutical University, Nanjing, People′s Republic of China

3 Department of Biochemistry, School of Life Science and Technology, China Pharmaceutical University, Nanjing, People′s Republic of China

* These authors have contributed equally to this work

Correspondence to:

Tao Xi, email:

Yingying Xing, email:

Keywords: STARD13; 3′UTRs; ceRNA; breast cancer metastasis; EMT

Received: December 11, 2015 Accepted: February 28, 2016 Published: March 15, 2016

Abstract

Competing endogenous RNAs (ceRNAs) network has been correlated with the initiation and development of cancer. Here, we identify CDH5, HOXD1, and HOXD10 as putative STARD13 ceRNAs and they display concordant patterns with STARD13 in different metastatic potential breast cancer cell lines and tissues. Notably, 3′UTRs of these genes suppress breast cancer metastasis via inhibiting epithelial-mesenchymal transition (EMT) in vitro and in vivo, which are activated through the crosstalk between STARD13 and its ceRNAs in 3′UTR- and miRNA-dependent manners. In addition, Kaplan-Meier survival analysis reveals that mRNA level of STARD13 and its ceRNAs is remarkably associated with survival of breast cancer patients. These results suggest that 3′UTRs of CDH5, HOXD1, and HOXD10 inhibit breast cancer metastasis via serving as STARD13 ceRNAs.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8099

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer

Abstract